Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
Los Bonos 1, 2 y 3 se encuentran actualmente cerrados. En las próximas semanas se proporcionará más información acerca de su apertura de cara a 2025.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
131
resultados
Última actualización
24/11/2024 [07:33:00]
Resumen de: WO2024235367A1
The present invention is related to the biomedical and biopharmaceutical sectors. Specifically, it relates to a chimeric antigen comprising the combination of the amino and carboxyl terminal regions of the amyloid beta peptide (Aβ), the amino and carboxyl terminal regions of the tau protein and a T cell epitope. The pharmaceutical composition comprising this chimeric antigen and at least one pharmaceutically acceptable vaccine adjuvant increases the efficacy of immunotherapy for the prevention and treatment of Alzheimer's Disease (AD). The chimeric antigen exerts its action by stimulating a multitarget humoral response with high titers of anti-Aβ and anti-tau antibodies simultaneously. This favors the combined elimination of toxic species of both Aβ and tau from the brain, which prevents or significantly improves the clinical symptoms and neuropathology of AD.
Resumen de: WO2024236054A1
The present invention discloses a compound represented by Formula (I): (I) or a radioactively labelled compound or pharmaceutically acceptable salt thereof for use as radioctive tracer compounds in monitoring a disease therapy in an individual. The present invention also discloses the compound or a radioactively labelled compound or pharmaceutically acceptable salt thereof or a composition for use in in vivo monitoring of an early stage of diseases, preferably Parkinson's disease, Multiple System Atrophy, Dementia with Lewy Bodies.
Resumen de: US2024383869A1
There are provided Tissue Transglutaminase (TG2) inhibitor compounds, and compositions and methods of use thereof for the prevention or treatment of a disease state mediated by TG2, such as a cancer, a neurodegenerative disease such as Huntington's disease, fibrosis, or Celiac disease. Compounds of Formula I, and pharmaceutically acceptable salts thereof, are provided: Formula (I)
Resumen de: US2024383901A1
Disclosed are compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. Also disclosed are methods of using such compounds as inhibitors of LRRK2, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating neurodegenerative diseases such as Parkinson's disease.
Resumen de: US2024382466A1
A pharmaceutical composition for preventing or treating Alzheimer's disease and use thereof are disclosed and belong to the technical field of medicines. The pharmaceutical composition includes (Z)-3-(N-(3-bromo-4-fluorophenyl)-N′-hydroxyformamido)-4-(2-guanidinoethyl)amino)-1,2, 5-oxadiazole and anhydroicaritin. A pharmacodynamic experiment proves that the pharmaceutical composition achieves a synergistic therapeutic effect on treating Alzheimer's disease.
Resumen de: US2024383972A1
The present disclosure relates to methods of slowing cognitive decline in mild-to-moderate and moderate Alzheimer's disease, and other Tau pathologies, using anti-Tau antibodies. The disclosure provides first-in-class immunotherapy for use in reducing clinical decline in mild-to-moderate AD and moderate AD, in particular, significantly reducing rate of decline in cognitive capacity to a clinically meaningful extent, and significantly retaining memory. The disclosure also relates to use of anti-Tau antibodies to intercept cell-to-cell spread of pathological Tau in the brains of patients with AD or related Tauopathies.
Resumen de: US2024382456A1
Disclosed are methods for inhibiting the progression of amyotrophic lateral sclerosis (ALS) in humans. The methods use a synergistic combination of 2,4-dihydro-3H-pyrazol-3-one and deuterated arachidonic acid or a prodrug thereof, such as 11,11-D2-linoleic acid or an ester thereof.
Resumen de: WO2024238879A1
The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/ Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)ZCoronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.
Resumen de: US2024383853A1
The present invention relates to oximes, their synthesis, and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.
Resumen de: WO2024236159A1
The present invention relates to the use of the HIP/PAP protein, or a derivative thereof, in the treatment and prevention, and in particular in the treatment, of a cognitive disorder associated with anxiety disorder(s) in an individual in need thereof, as well as for improving cognition in an individual affected by a neurological disorder associated with anxiety disorder(s) or for alleviating cognitive deficit in an individual affected by a disorder selected from the group consisting of Obsessive-compulsive disorder, Attention deficit disorder, Dementia with Lewy bodies disease, Early onset dementia, Epilepsy-related cognitive dysfunction, Fronto-temporal dementia, Posterior cortical atrophy, Huntington's disease (HD), Parkinson's disease, bipolar disorder, substance abuse, attention deficit disorders, psychotic disorders and a sars-cov-2 infection, and also in the prevention and/or treatment of diet induced cognitive and anxiety deficits in an individual in need thereof, and in particular high fat diet induced cognitive and anxiety deficits.
Resumen de: WO2024236367A2
Disclosed are methods of treating amyotrophic lateral sclerosis (ALS). Also disclosed are methods of treating C9orf72 amyotrophic lateral sclerosis (C9-ALS).
Resumen de: WO2024238387A1
A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
Resumen de: AU2023263890A1
The present invention relates to an isobenzofuran-1(3H)-one derivative, which is a kinase inhibitor, and a use thereof and, more specifically, to an isobenzofuran-1(3H)-one derivative having HPK1 inhibitory activity and MLK3 inhibitory activity and a pharmaceutical composition containing same for preventing or treating cancer, virus infectious diseases, Parkinson's disease, non-alcoholic steatohepatitis, or tuberculosis. In addition, the compound can be advantageously used as a composition for prevention or treatment of cancer as it is administered in combination with an anticancer agent or a cell therapy product.
Resumen de: AU2023251179A1
Disclosed herein are human blood fractions depleted of disease-causing extracellular vesicles, prepared by plasma exchange, that may find use in the treatment of a condition selected from the group consisting of neurodegenerative disease, autoimmune disease, cardiovascular disease, renal disease, and liver disease. In particular, the depleted blood fractions may find use in treating neurodegenerative diseases such as Parkinson's Disease or Alzheimer's Disease.
Resumen de: EP4464329A1
The present invention relates to a pharmaceutical composition for preventing or treating degenerative brain diseases by using glucagon-like peptide-1 (GLP-1) and an interleukin-1 receptor antagonist (IL-1Ra). A composition comprising a fusion protein including GLP-1 and IL-1Ra, according to the present invention, exhibits the effects of inhibiting the production of amyloid beta, which is known as a material causing Alzheimer's disease, and improving memory and cognitive function. In addition, it has been identified that when a bispecific antibody comprising GLP-1 and an anti-IL-1 antibody or a fusion protein in which II,-1Ra and Fc are linked is administered, amyloid beta plaque deposition in the brain is decreased and a neurogenesis promotion effect is exhibited in Alzheimer's disease model mice. Moreover, it has been identified that when GLP-1 and II,-1Ra are also co-administered, amyloid beta plaque deposition in the brain is decreased in Alzheimer's disease model mice. Therefore, the composition comprising GLP-1 and IL-1R, according to the present invention, can be effectively used in the prevention or treatment of degenerative brain diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease, and the alleviation of cognitive impairment.
Resumen de: EP4464330A1
The present invention relates to the use of the HIP/PAP protein, or a derivative thereof, in the treatment and prevention, and in particular in the treatment, of a cognitive disorder associated with anxiety disorder(s) in an individual in need thereof, as well as for improving cognition in an individual affected by a neurological disorder associated with anxiety disorder(s) or for alleviating cognitive deficit in an individual affected by a disorder selected from the group consisting of Obsessive-compulsive disorder, Attention deficit disorder, Dementia with Lewy bodies disease, Early onset dementia, Epilepsy-related cognitive dysfunction, Fronto-temporal dementia, Posterior cortical atrophy, Huntington's disease (HD), Parkinson's disease, bipolar disorder, substance abuse, attention deficit disorders, psychotic disorders and a sars-cov-2 infection.
Resumen de: US2024374553A1
Compositions comprising Zinc CARBONYL (ZNCO) and silicon SiHR57 molecules and protocols for their delivery to persons are disclosed, for mitigating and remediating neurodegenerative and cardiovascular diseases. The compositions and protocols are based upon the dissolution properties of neurotoxic compounds accumulated in brain tissues, the use of magnetic sources generating external electromagnetic radio waves or fields and the use of quantum tools such as NMRi and MHD-MGD to support molecular flows.
Resumen de: US2024376059A1
The present disclosure provides compounds that are amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the amylin receptor antagonists for treating, preventing, or ameliorating Alzheimer's disease. Aspects of the present disclosure include a method of inhibiting activity of an amylin receptor by administering to a subject in need thereof a therapeutically effective amount of an amylin receptor antagonist.
Resumen de: US2024376062A1
Sulfonylamide and sulfonyl urea compounds, pharmaceutical compositions comprising same, and methods of treating diseases or disorders associated to amyloidogenesis activity with such compounds are disclosed.
Resumen de: US2024376452A1
Provided are new compositions and methods useful for the treatment, prevention, and potential cure of Alzheimer's Disease by disrupting the genomic locus of IL1LR1 gene including rs1921622 and/or other 574 sST2-associated genomic sites and/or 3′-UTR of sST2 gene/transcript.
Resumen de: WO2024231837A1
The present invention relates to new boron-based compounds for the treatment of Alzheimer's disease by irradiation with neutrons amplified by neutron capture reactions (Capture-Enhanced Neutron Irradiation, CENI), and the relative preparation methods.
Resumen de: US2024374563A1
The present invention relates to an anticholinergic compound such as Darifenicin for use in the treatment of a neuromuscular disorder (in particular amyotrophic lateral sclerosis or ALS) in a human subject, wherein the neuromuscular disorder is characterized by an impaired neuromuscular transmission and/or an denervation at the NMJ (neuromuscular junction) and the anticholinergic agent is administered after symptomatic onset.
Resumen de: US2024374530A1
Disclosed is the obtaining of exosomes from coffee, ginkgo-biloba, and ginseng plants and making tablets from the exosomes. The use of plant-derived exosomes obtained from coffee, ginkgo-biloba, and ginseng, with high bio-compatibility, cellular uptake, stability, and much more ability to penetrate the blood-brain barrier is also disclosed in the treatment of Alzheimer's disease, cognitive dysfunction, forgetfulness, and poor concentration disorders.
Resumen de: US2024374739A1
The present invention relates to compounds having a range of beneficial therapeutic properties and effects, including neuroprotective effects, anti-inflammatory activity, antioxidative properties, and epithelial cell protective effects. These properties enable the compounds to be useful for treating or preventing a wide range of disorders and conditions. The disorders and conditions include neurological disorders (including neurodegenerative conditions such as Alzheimer's disease, dementia caused by Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (motor neurone disease), multiple sclerosis and brain injury), the cognitive decline associated with these neurological disorders (such as memory loss), and disorders caused by stress-induced cellular damage in the inner or middle ear of a subject (such as vestibular disorders, hearing impairment, and conditions related to hair cell degeneration or hair cell death).
Nº publicación: US2024376469A1 14/11/2024
Solicitante:
IONIS PHARMACEUTICALS INC [US]
Ionis Pharmaceuticals, Inc
Resumen de: US2024376469A1
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of HTT RNA in a cell or subject, and in certain instances reducing the amount of HTT protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom or hallmark of a repeat expansion disease. Such repeat expansion diseases include myotonic dystrophy, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington's disease, polyglutamine disorders, Fragile X syndrome, and spinocerebellar ataxia. Such symptoms or hallmarks include brain atrophy, muscle atrophy, nerve degeneration, uncontrolled movement, seizure, tremor, anxiety, and depression.
BOPI
Sede Electrónica
